Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
- General Phenotypes of Psychiatric Disorders Observed in iPS Cell Research: Sumitomo Dainippon, Keio Univ., Nagoya Univ.
October 25, 2019
- Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
- Shionogi to Focus on Safety, Not Sales, in Detailing Xofluza
October 25, 2019
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- Takeda Bags Worldwide Rights for Cour's Celiac Disease Treatment
October 24, 2019
- RWD Suggests Lower Serious Adverse Event Risks for Entyvio vs. Anti-TNFα Antibodies: Takeda
October 24, 2019
- Zolgensma’s Japan Launch Delayed into 2020 as Sakigake Review Drags On, MHLW Still Eager to Make Decision by Year-End
October 23, 2019
- Tecentriq plus Avastin Extend OS, PFS in 1st Line HCC
October 23, 2019
- In Shocking U-Turn, Biogen/Eisai Say to File Aducanumab in Early Next Year
October 23, 2019
- Parexel Looks to Set Itself Apart from Rivals through Consulting Services
October 23, 2019
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- JAK Debuts Draw Near in Japan Atopic Dermatitis Market, 1st Likely to Get Listing Next Spring
October 21, 2019
- FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019
- Shionogi, Janssen, Alzheimer’s Drug Discovery Foundation Join Forces to Develop AD Biomarkers
October 21, 2019
- Kyowa Kirin Recalling Mitomycin over Unauthorized Manufacturing Method, Supply Won’t Resume until 2021
October 18, 2019
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Sumitomo Dainippon Drops Bid to Buy Cynata
October 18, 2019
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…